Michele Vizzi

Dr. Michele Vizzi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Elena BertelliElena Bertelli
Elena Bertelli
MVMichele Vizzi
Michele Vizzi
Chiara MarziChiara Marzi
Chiara Marzi
SPSandro Pastacaldi
Sandro Pastacaldi
ACAlberto Cinelli
Alberto Cinelli
VMVittorio Miele
Vittorio Miele
Background: Biparametric MRI (bpMRI) has an important role in the diagnosis of prostate cancer (PCa), by reducing the cost and duration of the procedure and adverse reactions. We assess the additional benefit of the ADC map in detecting prostate cancer (PCa). Additionally, we examine whether the ADC value correlates with the presence of clinically significant tumors (csPCa). Methods: 104 peripheral lesions classified as PI-RADS v2.1 score 3 or 3+1 at the mpMRI underwent transperineal MRI/US fusion-guided targeted biopsy. Results: The lesions were classified as PI-RADS 3 or 3+1; at histopathology, 30 were adenocarcinomas, 21 of which were classified as csPCa. The ADC threshold that maximized the Youden index in order to predict the presence of a tumor was 1103 (95% CI (990, 1243)), with a sensitivity of 0.8 and a specificity of 0.59; both values were greater than those found using the contrast medium, which were 0.5 and 0.54, respectively. Similar results were also found with csPCa, where the optimal ADC threshold was 1096 (95% CI (988, 1096)), with a sensitivity of 0.86 and specificity of 0.59, compared to 0.49 and 0.59 observed in the mpMRI. Conclusions: Our study confirms the possible use of a quantitative parameter (ADC value) in the risk stratification of csPCa, by reducing the number of biopsies and, therefore, the number of unwarranted diagnoses of PCa and the risk of overtreatment.

20 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Elena BertelliElena Bertelli
Elena Bertelli
MVMichele Vizzi
Michele Vizzi
MLMartina Legato
Martina Legato
RNRossella NICOLETTI
Rossella NICOLETTI
SPSebastiano Paolucci
Sebastiano Paolucci
VMVittorio Miele
Vittorio Miele
Background/Purpose: to assess the inter-reader agreement of the PIFAB (Prostate Imaging after Focal Ablation) score, a new MRI-based standardized system for evaluating post-focal therapy prostate mpMRI, among radiologists in a single large cohort of patients treated with focal therapy (HIFU) in a tertiary care referral University Hospital. Methods: In total, 68 consecutive patients who underwent HIFU were included in this single-center retrospective observational study. A total of 109 post-HIFU follow-up mpMRIs were evaluated by three radiologists with varying levels of experience (12, 8, and 3 years, respectively). All patients underwent their first follow-up mpMRI at 6 months post-treatment, with 30 patients receiving additional evaluations at 18 months and 11 at 30 months. Results: The patients had a mean age of 70.6 ± 8.31 years, a mean pre-treatment PSA (prostate-specific antigen) of 7.85 ± 1.21 ng/mL, and a mean post-treatment PSA of 4.64 ± 4.2 ng/mL. The inter-reader agreement for PI-FAB among the three radiologists showed a Gwet’s AC2 value of 0.941 (95% confidence interval: 0.904–0.978, p < 0.0001). For the most experienced radiologist, at the 6-month follow-up 64 (94.14%) patients were scored as PI-FAB 1, 1 (1.47%) as PI-FAB 2, and 3 (4.41%) as PI-FAB 3. At the 18-month and 30-month follow-ups all patients were scored as PI-FAB 1 (no suspicion of recurrence). Conclusions: Our study demonstrates excellent inter-reader agreement among radiologists with varying levels of experience, confirming that the PI-FAB score is highly reproducible when evaluating post-treatment mpMRI scans. The low rate of PI-FAB 2 and PI-FAB 3 lesions observed at the first follow-up, coupled with the absence of significant recurrence in subsequent evaluations, suggests that HIFU is a reliable technique for prostate cancer treatment in selected patients.

31 March 2025 in Ultraschall in der Medizin - European Journal of Ultrasound
Verified
Journal Article
Closed access
Elena BertelliElena Bertelli
Elena Bertelli
MVMichele Vizzi
Michele Vizzi
LLLorenzo Lattavo
Lorenzo Lattavo
RRRon Ruzga
Ron Ruzga
SGSimona Giovannelli
Simona Giovannelli
VMVittorio Miele
Vittorio Miele
Evaluation of the possible role of microvascular imaging (MI) for the detection of vascularization of renal lesions, while comparing it with contrast-enhanced ultrasound (CEUS).137 patients (160 renal lesions, 64 solid and 96 cystic) were enrolled in this single-center, retrospective, observational study. For solid masses, both the intralesional and the peripheral vascularization was analyzed and quantified by MI and then compared to peak enhancement on CEUS. Regarding cystic lesions, we evaluated the presence or absence of vascularization within the cystic wall and/or septa. MI results were compared with CEUS findings using Pearson’s Chi square test. An optimal size cut-off for renal lesions was determined with the Youden test.For solid lesions, a statistically significant correlation (p <0.05) was observed between the MI parameters and the peak enhancement on CEUS. The detection rate (DR) for lesional vascularization on MI was 87.5%, while if we consider only lesions larger than the optimal cut-off (14mm), the DR increases to 98%. In cystic lesions, the MI showed a high specificity (93.9%) in predicting CEUS results and a high positive predictive value (84.2%). The concordance was 100% in Bosniak I lesions and 80% in Bosniak IV lesions, while it was lower for the other classes. Furthermore, we found a statistically significant correlation (p <0.05) between Bosniak grade and lesional vascularity on MI.Our preliminary study shows that MI cannot replace CEUS, but could reduce its use, especially in solid lesions larger than 14mm and in cysts classified as Bosniak IV, a goal that is particularly important in an active surveillance setting.